SCHEMBL1986996

SCHEMBL1986996

O=C(Nc1ccc(Cl)cc1)c1ccc(Cl)nc1

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 9/20 0.82
KCNQ2 O43526 9/20 0.82
KCNE1 P15382 7/20 0.82
KCNQ1 P51787 7/20 0.82
RAB9A P51151 2/20 0.77
SMN1; SMN2 Q16637 2/20 0.77
P4HTM Q9NXG6 1/20 0.70
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
LMNA P02545 2/20 0.68
ALDH1A1 P00352 1/20 0.68
BACE1 P56817 1/20 0.65
MAPT P10636 5/20 0.63
HTT P42858 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63
EGFR P00533 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217440 0.90 KCNQ3 (1.00) KCNQ3KCNQ2KCNE1KCNQ1RAB9A
SCHEMBL5215207 0.90 KCNQ3 (0.81) KCNQ3KCNQ2KCNE1KCNQ1RAB9A
SCHEMBL3313800 0.89 RAB9A (0.75) KCNQ3KCNQ2KCNE1KCNQ1RAB9A
SCHEMBL11555293 0.88 KCNQ3 (0.64) KCNQ3KCNQ2KCNE1KCNQ1RAB9A
SCHEMBL2801974 0.87 KCNQ3 (0.85) KCNQ3KCNQ2KCNE1KCNQ1RAB9A
SCHEMBL8361559 0.87 RAB9A (1.00) KCNQ3KCNQ2KCNE1KCNQ1RAB9A
SCHEMBL2306301 0.87 RAB9A (0.76) KCNQ3KCNQ2KCNE1KCNQ1RAB9A
SCHEMBL403003 0.85 KCNQ3 (0.68) KCNQ3KCNQ2KCNE1KCNQ1RAB9A
SCHEMBL1844238 0.84 RAB9A (0.74) KCNQ3KCNQ2KCNE1KCNQ1RAB9A
SCHEMBL2302748 0.84 RAB9A (0.74) KCNQ3KCNQ2KCNE1KCNQ1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222275-B2 Biarylcarboxyarylamides as vanilloid-1 receptor modulators PHARMESTE S.R.L. (IT) 2012-07-17 US disclosed
CN-101490006-B Biaryl carboxylic acid arylamides as vanilloid-1 receptor modulators PHARMESTE SRL 2012-05-23 CN disclosed
EP-2041094-B1 BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS PHARMESTE SRL (IT) 2011-06-29 EP disclosed
US-20100081687-A1 BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS PHARMESTE S.R.L. (IT) 2010-04-01 US disclosed
CN-101490006-A Biaryl carboxylic acid arylamides as vanilloid-1 receptor modulators PHARMESTE SRL (IT) 2009-07-22 CN disclosed
EP-2048133-A1 Nicotinamide n-oxide derivatives as vanilloid-1 receptor modulators Pharmeste S.r.l. (IT) 2009-04-15 EP disclosed
WO-2009043582-A1 NICOTINAMIDE N-OXIDE DERIVATIVES AS VANILLOID-1 RECEPTOR MODULATORS PHARMESTE S.R.L. (IT) 2009-04-09 WO disclosed
EP-2041094-A1 BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS Pharmeste S.r.l. (IT) 2009-04-01 EP disclosed
WO-2008006480-A1 BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS PHARMESTE S.R.L. (IT) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081687-A1 BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS TRPV1, TRPV3, TRPV2 KCNQ3 400/4885KCNQ2 398/4885KCNE1 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.